Agilent Technologies Inc (A)vsNovo Nordisk A/S (NVO)
A
Agilent Technologies Inc
$115.62
-2.55%
HEALTHCARE · Cap: $33.53B
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 4540% more annual revenue ($327.80B vs $7.07B). NVO leads profitability with a 37.2% profit margin vs 18.3%. A appears more attractively valued with a PEG of 1.23. NVO earns a higher WallStSmart Score of 74/100 (B).
A
Buy61
out of 100
Grade: C+
NVO
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-45.8%
Fair Value
$88.39
Current Price
$115.62
$27.23 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 20 in profit
Strong operational efficiency at 22.9%
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Areas to Watch
Moderate valuation
Grey zone — moderate risk
Weak financial health signals
Earnings declined 3.6%
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : A
The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
A profiles as a mature stock while NVO is a growth play — different risk/reward profiles.
A carries more volatility with a beta of 1.22 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 61/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?